Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer

Sarah Einerhand(The Netherlands Cancer Institute), Laura S. Mertens(Oncode Institute), Niels-Erik Jacobson(University of Alberta), Maria Carmen Mir(Fundación Instituto Valenciano de Oncología), Andrew C. Thorpe(Freeman Hospital), Évanguelos Xylinas(NewYork–Presbyterian Hospital), Wassim Kassouf(McGill University), Petros Grivas(Seattle Cancer Care Alliance), Todd M. Morgan(University of Michigan), Homayoun Zargar(University of British Columbia), Philippe E. Spiess(Moffitt Cancer Center), Yair Lotan(Southwestern Medical Center), Srikala S. Sridhar(Princess Margaret Cancer Centre), Siamak Daneshmand(Unknown), Adrian Fairey(University of Alberta), Peter C. Black(University of British Columbia), Michael S. Cookson(University of Oklahoma Health Sciences Center), Nikhil Vasdev(University of Hertfordshire), Jay B. Shah(The University of Texas MD Anderson Cancer Center), Kamran Zargar‐Shoshtari(University of Auckland), Scott North, Daniel A. Barocas(Vanderbilt University Medical Center), Anna J. Black(University of British Columbia), Jonathan McGrath(Royal Devon & Exeter NHS Foundation Trust), Trinity J. Bivalacqua(University of Pennsylvania), Shahrokh F. Shariat(Universitätszahnklinik Wien), Jonathan L. Wright(Seattle University), Laura‐Maria Krabbe, Marc Dall’Era(University of California, Davis), Evan Y. Yu(University of Washington), Andrew J. Stephenson(Republic of Korea Army), Jorge A. García(Cleveland Clinic), Bas W.G. van Rhijn(The Netherlands Cancer Institute), Jeff M. Holzbeierlein(University of Kansas), Jonathan Aning(Royal Devon and Exeter Hospital), Jeffrey S. Montgomery(Ann Arbor Center for Independent Living), Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
World Journal of Urology
September 28, 2022
Cited by 10


Related Papers